- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00879814
Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults
A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Florida
-
South Miami, Florida, États-Unis, 33143
- Miami Research Associates, Inc.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
A subject must meet the following inclusion criteria at screening (visit 1) and at randomization (visit 2) to be considered for enrollment in the study:
- Male or female subjects between the ages of 18 and 40.
- Healthy male or female subjects as determined by medical history, physical examination, and judgment of the investigator.
- Male or female subject who is considered biologically capable of having children must agree to commit to the use of a reliable method of birth control for the duration of the study and for 30 days after early discontinuation. A subject is still biologically capable of having children, even if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.
In addition a subject must meet the following inclusion criteria at randomization (visit 2) to be considered for enrollment in the study. The referred blood and urinalysis tests (inclusion criterion 5) will be performed on a blood and urine sample taken at visit 1:
- Female subjects of childbearing potential with a negative urine pregnancy test prior to study drug administration. Note: this criterion will apply to each vaccination visit and to the last study visit.
- Laboratory blood and urinalysis tests results within the per-protocol normal ranges.
- Able to be contacted by telephone during the study period. Note: this criterion will apply to each study visit.
Exclusion Criteria:
None
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: 1
rLP2086 vaccine 60 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
Expérimental: 2
rLP2086 vaccine 120 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
Expérimental: 3
rLP2086 vaccine 200 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
Comparateur actif: 4
Tdap vaccine - normal saline - normal saline
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Percentage of Participants With at Least One Adverse Event (AE)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alanine Aminotransferase [ALT])
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Aspartate Aminotransferase [AST])
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Protein)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Albumin)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alkaline Phosphatase [ALP])
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Bilirubin)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Creatine Phosphokinase [CPK])
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Prothrombin Time [PT])
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Partial Thromboplastin Time [PTT])
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Fibrinogen)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Hemoglobin)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (White Blood Cell [WBC])
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Lymphocytes)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Neutrophils)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Eosinophils)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Platelet Count)
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Sodium).
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Potassium).
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Blood Urea Nitrogen [BUN]).
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Serum Creatinine).
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Red Blood Cells [RBC]).
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Protein).
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Glucose).
Délai: Baseline up to Month 7
|
Baseline up to Month 7
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Meningococcal Immunoglobulin G (IgG) Geometric Mean Titers (GMT)
Délai: Before Dose 1, 1 month after Dose 2, before Dose 3, 1 month after Dose 3
|
Before Dose 1, 1 month after Dose 2, before Dose 3, 1 month after Dose 3
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11.
- Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother. 2012 Jul;8(7):888-95. doi: 10.4161/hv.19983. Epub 2012 Jul 1.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux central
- Maladies du système nerveux
- Infections
- Infections du système nerveux central
- Infections bactériennes à Gram négatif
- Infections bactériennes
- Infections bactériennes et mycoses
- Méningite bactérienne
- Infections bactériennes du système nerveux central
- Infections méningococciques
- Infections à Neisseriacées
- Méningite, méningocoque
- Méningite
- Effets physiologiques des médicaments
- Facteurs immunologiques
- Vaccins
Autres numéros d'identification d'étude
- 6108A1-1004
- B1971004 (Autre identifiant: Alias Study Number)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .